Indivior PLC Ordinary Shares Market Cap ($3.91 Billion)
Market Cap & Net Worth: Indivior PLC Ordinary Shares (INDV)
Indivior PLC Ordinary Shares market cap. Indivior PLC Ordinary Shares (NASDAQ:INDV) has a market capitalization of $3.91 Billion ($3.91 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4041 globally and #1436 in its home market, demonstrating a 0.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indivior PLC Ordinary Shares's stock price $35.37 by its total outstanding shares 124853897 (124.85 Million). Also see INDV cash generation efficiency for how efficiently the company converts equity into cash flow.
Indivior PLC Ordinary Shares Market Cap History (2015–2026)
Indivior PLC Ordinary Shares market cap history from 2015 to 2026. Data shows growth from $289.20 Million to $4.42 Billion (26.14% CAGR). Check INDV live share price for real-time trading data and today's change.
Index Memberships
Indivior PLC Ordinary Shares is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.15% | #107 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #469 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.21% | #68 of 263 |
Weight: Indivior PLC Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indivior PLC Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indivior PLC Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Indivior PLC Ordinary Shares to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.31x
Indivior PLC Ordinary Shares's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
775.97x
Indivior PLC Ordinary Shares's market cap is 775.97 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $443.23 Million | $968.89 Million | $32.05 Million | 0.46x | 13.83x |
| 2017 | $686.57 Million | $1.15 Billion | $60.92 Million | 0.60x | 11.27x |
| 2018 | $168.55 Million | $959.92 Million | $262.67 Million | 0.18x | 0.64x |
| 2019 | $64.92 Million | $815.16 Million | $139.15 Million | 0.08x | 0.47x |
| 2020 | $182.91 Million | $689.68 Million | -$157.76 Million | 0.27x | N/A |
| 2021 | $430.75 Million | $777.48 Million | $205.00 Million | 0.55x | 2.10x |
| 2022 | $2.72 Billion | $884.63 Million | -$52.04 Million | 3.07x | N/A |
| 2023 | $1.91 Billion | $1.09 Billion | $2.00 Million | 1.74x | 953.26x |
| 2024 | $1.55 Billion | $1.19 Billion | $2.00 Million | 1.31x | 775.97x |
Competitor Companies of INDV by Market Capitalization
Companies near Indivior PLC Ordinary Shares in the global market cap rankings as of November 1, 2026. Also see Indivior PLC Ordinary Shares balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Indivior PLC Ordinary Shares by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Indivior PLC Ordinary Shares (2015–2026)
Market capitalization of Indivior PLC Ordinary Shares from 2015 to today. Between 2015 and today, Indivior PLC Ordinary Shares's market cap moved from $289.20 Million to $ 4.42 Billion, with a yearly change of 26.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.42 Billion | -1.42% |
| 2025 | $4.48 Billion | +188.66% |
| 2024 | $1.55 Billion | -18.60% |
| 2023 | $1.91 Billion | -29.79% |
| 2022 | $2.72 Billion | +530.43% |
| 2021 | $430.75 Million | +135.49% |
| 2020 | $182.91 Million | +181.73% |
| 2019 | $64.92 Million | -61.48% |
| 2018 | $168.55 Million | -75.45% |
| 2017 | $686.57 Million | +54.90% |
| 2016 | $443.23 Million | +53.26% |
| 2015 | $289.20 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Indivior PLC Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.91 Billion USD |
| MoneyControl | $3.91 Billion USD |
| MarketWatch | $3.91 Billion USD |
| marketcap.company | $3.91 Billion USD |
| Reuters | $3.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more